
ABSTRACT Background Osteosarcopenia, the coexistence of osteoporosis and sarcopenia, has emerged as a candidate musculoskeletal aging syndrome, supported by a growing body of mechanistic evidence on crosstalk between bone, muscle and adipose tissue, including mechanotransduction, myokine and osteokine signalling, inflammaging, mitochondrial dysfunction, marrow adiposity, myosteatosis and impaired regenerative capacity. Whether this biological convergence translates into a prognostically autonomous clinical entity remains uncertain. Operational definitions still combine criteria developed separately for osteoporosis and sarcopenia, biologically integrated diagnostic frameworks and validated biomarkers are lacking and longitudinal cohorts differ substantially in case definitions, populations and adjustment strategies. In this narrative review we critically appraise the biological, diagnostic and epidemiological evidence on osteosarcopenia, focusing on hard clinical endpoints (mortality, fractures, falls). Methods Narrative review based on a structured search of PubMed/MEDLINE, Scopus and Web of Science (inception to October 2026), prioritizing prospective cohorts reporting mortality, fractures, or falls, meta‐analyses and consensus documents. Results Prospective studies suggest that osteosarcopenia identifies older adults at increased risk of adverse outcomes; however, recent meta‐analytic evidence, including formal interaction analyses, does not consistently support additive or multiplicative effects beyond isolated osteoporosis or sarcopenia alone. Fracture risk appears largely driven by skeletal fragility, while mortality associations overlap substantially with frailty burden and aging‐related vulnerability. Conclusions Osteosarcopenia is best understood, at present, as a marker of integrated musculoskeletal vulnerability along an aging continuum rather than a discrete syndrome. Future research should prioritize harmonized definitions, biologically integrated phenotyping and adequately powered cohorts capable of testing interaction effects between skeletal and muscular impairment.
ABSTRACT Background Phenotype‐oriented management is increasingly advocated in recurrent pericarditis (RP), but it remains unclear whether clinically recognizable phenotypes reflect underlying disease biology or are shaped by current inflammation and treatment exposure. We used multidimensional phenomapping to investigate this heterogeneity. Methods We analysed 101 patients with idiopathic RP from the multicenter PERIPLO cohort. Factor analysis of mixed data followed by hierarchical clustering defined the index solution. Robustness was assessed across alternative specifications and models excluding treatment, inflammatory state or the IL‐1Ra axis. Results Three clinical–immunological patterns emerged: a predominantly remission‐state, anakinra‐treated group; a predominantly remission‐state group largely managed without IL‐1 blockade; and an active inflammatory group enriched for anti‐IL‐1Ra autoantibodies and characterized by markedly reduced measured IL‐1Ra. The two antibody‐negative groups were extensively reorganized after treatment variables were removed, whereas exclusion of the IL‐1Ra axis nearly abolished agreement with the original partition. In contrast, anti‐IL‐1Ra positivity remained consistently associated with active inflammation and very low measured IL‐1Ra. Conclusions In this cohort, the phenotypic heterogeneity of RP was better represented as a clinical–immunological spectrum shaped by inflammatory state and treatment exposure than as discrete, stable endotypes. The anti‐IL‐1Ra‐associated inflammatory signature was the most internally consistent biological signal. These exploratory findings require external validation, and longitudinal multidimensional phenomapping should test whether this signature can inform patient management.
Mucosa-associated invariant T (MAIT) cells are innate-like MR1-restricted T cells broadly distributed in human tissues. MAIT cells adapt their antigen-specific response patterns depending on cytokine cues such as IL-12 or IL-18 in the microenvironment, shifting toward either IL-10+ or IL-17+ profiles. However, if such patterns are maintained in the context of inflammatory diseases is unknown. Here, we investigated MAIT cell functional plasticity in Crohn's disease (CD). Circulating MAIT cells in CD patients were impaired both in terms of numbers, and in terms of interferon gamma (IFN-gamma) and tumor necrosis factor (TNF) expression, and cytotoxic properties in response to MR1-presented antigen. However, the MAIT cell regulatory IL-10+ profile and the IL-17A+ profile were compromised only during active disease and relatively preserved during remission. Transcriptional analysis of intestinal T cells suggested that MAIT cells in CD displayed elevated GNLY and NKG7 expression, while transcripts associated with regulation and quiescence characterized MAIT cells in healthy donor control tissue. There were also distinct transcriptional signatures according to localization, where intra-epithelial MAIT cells exhibited a tissue resident regulatory profile, whereas those in the lamina propria showed signs of activation and recruitment. Finally, we assessed whether treatments for CD influenced MAIT cell functionality in vitro. Corticosteroids and upadacitinib inhibited MAIT cell activation, yet upadacitinib promoted increased GM-CSF and IL-17A expression in the context of combined antigen and IL-18 stimulation. These findings indicate that MAIT cell functional response patterns are influenced by CD disease stage, treatment, and tissue localization.
CD8+ tissue-resident memory T cells (TRM) in the upper respiratory tract (URT) limit viral replication after transmission and prevent spread to the lower respiratory tract (LRT), whereas LRT CD8+ TRM are important for limiting immunopathology in the lung and promoting efficient viral clearance. Although the presence of local respiratory antigen is thought to be required for CD8+ TRM development in the LRT but not the URT, the relationship between local antigen encounter and cytokine signaling that influences TRM differentiation in distinct niches of the respiratory tract remains unknown. Here, we show using murine models that while URT TRM generated in the presence or absence of local respiratory antigen are phenotypically, transcriptionally, and functionally similar throughout the respiratory tract, their developmental pathways are compartmentally distinct and characterized by a context-dependent compensatory relationship between antigen and cytokine signaling. In the absence of local antigen, URT CD8+ TRM formation required TGF-beta signaling, and notably, while both IL-15 and IL-33 were broadly dispensable in the URT, IL-33 was able to rescue LRT CD8+ TRM development in the absence of local antigen. Together, these findings highlight key differences for CD8+ TRM development in distinct areas of the respiratory tract, offering valuable insights into the development of mucosal cellular immunity following intranasal and parenteral vaccination.
Background and Aims In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index >= 27 kg/m(2) without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this cardiovascular benefit. Methods Changes from randomization to 24 months in body weight, waist circumference, plasma high-sensitivity C-reactive protein (hsCRP), glycated haemoglobin (HbA(1c)), lipids, blood pressure, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio were examined individually, and in combination, as potential mediators of MACE risk reduction, using the Vansteelandt repeated regression method (a counterfactual approach). Results Semaglutide significantly (P < .05) improved all potential mediators investigated. Point estimates for % mediation were largest for waist circumference (64.0% [95% confidence interval (CI) 27.5, 179.6]), hsCRP (42.1% [17.9, 110.5]), HbA(1c) (29.0% [-20.7, 120.5]), and body weight (19.5% [-33.0, 110.7]), examined separately, but all had wide CIs. Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationship of body weight and waist change to MACE between treatment arms. Multivariable analysis estimated joint mediation for all potential mediators combined to be 31.4% (95% CI -30.1, 143.6). When variables other than body weight and waist circumference were considered, % mediation was 46.0% (95% CI -6.0, 161.0). Conclusions Mediation analyses could not fully ascribe the effects of semaglutide on MACE to known risk factors in SELECT with any certainty. Further investigation of potential additional biomarkers and mediators of semaglutide's cardiovascular protective effect are of interest. [GRAPHICS] .